Search

Your search keyword '"Scagliotti, Giorgio"' showing total 10 results
Start Over Author "Scagliotti, Giorgio" Journal cancer
10 results on '"Scagliotti, Giorgio"'

7. Gemcitabine and Cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB-nonsmall cell lung carcinoma

Author

Cappuzzo, Federico, Selvaggi, Giovanni, Gregorc, Vanesa, Mazzoni, Franscesca, Betti, Maura, Migliorino, Maria Rita, Novello, Silvia, Maestri, Antonio, Marinis, Filippo De, Darwish, Samir, Angelis, Verena De, Nelli, Fabrizio, Bartolini, Stefania, Scagliotti, Giorgio V., Tonato, Mauizio, and Crino, Lucio

Subjects
Lung cancer -- Care and treatment, Cisplatin -- Dosage and administration, Gemcitabine -- Dosage and administration, Health
Published
2003

8. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma

Author

Selvaggi, Giovanni, Scagliotti, Giorgio V., Torri, Valter, Novello, Silvia, Leonardo, Eugenio, Cappia, Claudio, Ardissone, Francesco, Lausi, Paolo, Borasio, Piero, and Mossetti, Claudio

Subjects
Medical research -- Analysis, Cancer -- Research, Gene expression -- Physiological aspects, Cancer survivors -- Health aspects, Cells -- Genetic aspects, Lung cancer -- Care and treatment, Excision (Surgery) -- Analysis, Health
Published
2002

9. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer: multicentric randomized FONICAP trial report

Author

Ardizzoni, Andrea, Salvati, Franco, Rosso, Riccardo, Bruzzi, Paolo, Rubagotti, Alessandra, Pennucci, Maria Cristina, Mariani, Gabriella Lucia, De Marinis, Filippo, Pallotta, Giovanni, Antilli, Antonio, Cruciani, Anna Maria, Rinaldi, Massimo, Tonachella, Riccardo, Soresi, Enzo, Pastorino, Gisella, Belli, Mario, Ferrara, Giuseppe, Venturini, Marco, Scagliotti, Giorgio, Santi, Leonardo, Fioretti, Marina, Barbera, Santi, and Mantellini, Ennio

Subjects
Lung cancer, Non-small cell, Chemotherapy, Combination -- Evaluation, Interferon alpha -- Evaluation, Health
Abstract

Background. Preclinical data suggested that alpha-interferon (IFN) may potentiate chemotherapy cytotoxicity. Methods. A prospective multicentric randomized trial was initiated to assess the clinical benefit of adding recombinant alpha-2-IFN to combination chemotherapy in patients with metastatic non-small cell lung cancer. A total of 182 patients were randomized to receive either cisplatin-epidoxorubicin-cyclophosphamide (CEP) combination chemotherapy (cisplatin, 60 mg/[m.sup.2;] epidoxorubicin, 50 mg/[m.sup.2]; and cyclophosphamide, 400 mg/[m.sup.2] intravenously) alone on day 1 or the same chemotherapy plus recombinant alpha-2-IFN at the doseof 5 MU intramuscularly from day -2 to +4, then 3 times weekly. Results. The median survival was 6 months in the CEP plus IFN arm versus 5.5 months in the control arm. The log-rank test showed a marginal statistically significant difference (P = 0.045) in favor of CEP chemotherapy, which disappeared when survival curves were adjusted for prognostic factors. Progression-free survival was similar in the two treatment arms. Considering all eligible patients, the response rate was 7.6% in the CEP arm versus 18.9% in the CEP plus IFN arm (P = 0.042). Nearly 40% of the patients receiving IFN ha grade 3-4 nadir leukopenia versus 15% in the control arm (P = 0.01) and 12.5% versus 4.2% had grade 3-4 thrombocytopenia. Apart from the usual constitutional symptoms, IFN was also responsible for increased emesis and mucositis. Conclusions. This study indicates that the addition of recombinant alpha-IFN to CEP chemotherapy can increase response rate and toxicity to treatment without a positive effect on progression-free survival and survival.

Published
1993

10. Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.

Author

Bironzo P, Cani M, Jacobs F, Napoli VM, Listì A, Passiglia F, Righi L, Di Maio M, Novello S, and Scagliotti GV

Subjects
Humans, Retrospective Studies, Proto-Oncogene Proteins p21(ras) genetics, Mutation, Immunotherapy, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms therapy, Lung Neoplasms drug therapy
Abstract

Background: KRAS mutation-positive (KRAS-positive), advanced nonsmall-cell lung cancer (NSCLC) is characterized by a poor prognosis. KRAS mutations are extremely heterogeneous from a biologic point of view, and real-world data by mutation subtype in the era of immunotherapy are still incomplete., Methods: The objective of this study was to retrospectively analyze all consecutive patients with advanced/metastatic, KRAS-positive NSCLC who were diagnosed at a single academic institution since the advent of immunotherapy. The authors report on the natural history of the disease as well as the efficacy of first-line treatments in the entire cohort and by KRAS mutation subtypes as well as the presence/absence of co-mutations., Results: From March 2016 to December 2021, the authors identified 199 consecutive patients who had KRAS-positive, advanced or metastatic NSCLC. The median overall survival (OS) was 10.7 months (95% confidence interval [CI], 8.5-12.9 months), and there were no differences by mutation subtype. Among 134 patients who received first-line treatment, the median OS was 12.2 months (95% CI, 8.3-16.1 months), and the median progression-free survival was 5.6 months (95% CI, 4.5-6.6 months). At multivariate analysis, only an Eastern Cooperative Oncology Group performance status of 2 was associated with significantly shorter progression-free survival and OS., Conclusions: KRAS-positive, advanced NSCLC is characterized by a poor prognosis despite the introduction of immunotherapy. Survival was not associated with KRAS mutation subtype., Plain Language Summary: This study evaluated the efficacy of systemic therapies for advanced/metastatic nonsmall cell lung cancer harboring KRAS mutations, along with the potential predictive and prognostic role of mutation subtypes. The authors found that advanced/metastatic, KRAS-positive nonsmall cell lung cancer is characterized by a poor prognosis and that first-line treatment efficacy is not related to different KRAS mutations, although a numerically shorter median progression-free survival was observed in patients who had p.G12D and p.G12A mutations. These results underline the need for novel treatment options in this population, such as next-generation KRAS inhibitors, which are in clinical and preclinical development., (© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results